Otsuka’s Voyxact (anti-APRIL) is raising expectations for an IgA nephropathy treatment reset after phase 3 eGFR slope data suggested it may halt or reverse kidney function decline. The program’s Phase 3 dataset—summarized as short-horizon renal performance—positions the therapy as a potential alternative route to disease control. As anti-APRIL strategies move through late-stage evaluation, eGFR slope remains a central efficacy lens used by clinicians and regulators to compare disease-modifying capacity across agents. Otsuka’s data narrative centers on whether treatment can change the trajectory rather than only provide symptom or proteinuria improvements. The readout also reinforces a competitive focus on IgA nephropathy as companies aim for earlier, durable kidney benefit claims that can influence prescribing and payer coverage decisions.